COMMUNIQUÉS West-GlobeNewswire

Novartis announces expiration of Tourmaline Bio tender offer
28/10/2025
Basel, October 28 2025 - Novartis today announced that its previously announced tender offer (the “offer”) by Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“ [...]
Swarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancers
28/10/2025
London, United Kingdom October 28, 2025, Swarm Oncology Ltd. (“Swarm Oncology” or “Swarm”), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid [...]
Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines
28/10/2025
COPENHAGEN, Denmark, October 28, 2025 – Bavarian Nordic announced today a donation of mpox vaccines to Africa CDC to support the response to the ongoing mpox outbreak in Africa. The donation of 110,000 doses of the [...]
Présentation du tout premier grand modèle de langage multiomique au monde au salon Global Health Exhibition de Riyad, ou la promesse d’un décodage du langage de la biologie humaine
28/10/2025
Entraîné à partir de données multiomiques, le modèle fondamental de PanOmiQ représente une percée grâce à son déploiement alimenté par des composants logiques programmables (ou FPGA, de l’anglais Field-Programmable Gate [...]
Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025
28/10/2025
Dubai, UAE / Beijing, China, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ: QLGN) (“Qualigen”, “QLGN” or the “Company”), a publicly-traded technology company majority owned by Faraday Future [...]
Positive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome
28/10/2025
Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52 If approved, Gazyva/Gazyvaro could help children and young adults sustain [...]
Communiqué de presse : Sanofi place 3 milliards de dollars d’emprunts obligataires
28/10/2025
Sanofi place 3 milliards de dollars d’emprunts obligataires Paris, 28 Octobre 2025 - Sanofi annonce avoir placé avec succès une émission obligataire en 5 tranches (les « obligations ») pour un montant de 3 milliards de [...]
Press release: Sanofi successfully prices USD 3 billion of bond issue
28/10/2025
Sanofi successfully prices USD 3 billion of bond issue Paris, France – October 28, 2025 - Sanofi announces that it has successfully priced its offering of $3 billion of notes across 5 tranches: $400 million fixed rate [...]
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
28/10/2025
Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +7% (cc 1 , +8% USD) and core operating income 1 grew +7% (cc, +6% USD) Sales growth was driven by continued strong execution on priority brands including [...]
Outset Medical to Report Third Quarter 2025 Financial Results on Monday, November 10, 2025
27/10/2025
SAN JOSE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, [...]
IRADIMED CORPORATION to Hold Third Quarter of 2025 Financial Results Conference Call on November 3, 2025
27/10/2025
ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 third quarter financial results before the market opens on Monday, November 3, [...]
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
27/10/2025
BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 10, 2025, to [...]
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
27/10/2025
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m [...]
MEDIA ADVISORY: Patients join Day of Action at Ontario Legislature to demand action on complaints about private clinics’ charges
27/10/2025
TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- On Wednesday October 29, patients who have been wrongfully charged for surgeries and diagnostic tests at private clinics will be joined by people from across Ontario at the [...]
BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant
27/10/2025
POMPANO BEACH, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Company”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental- [...]
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
27/10/2025
SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30 [...]
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
27/10/2025
BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric [...]
Amwell® to report third quarter 2025 operating results; company leaders to attend upcoming investor conferences
27/10/2025
BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report third quarter 2025 operating results [...]
Elixir Medical annonce de nouveaux résultats cliniques significatifs pour le DynamX® Bioadaptor, démontrant une réduction de près de 50 % des taux d’événements coronariens par rapport à la norme actuelle de soins ICP
27/10/2025
Les résultats ont été présentés lors de la Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 à San Francisco, le 27 octobre 2025 Le DynamX® Bioadaptor est la première technologie interventionnelle à [...]

Pages